Nd Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-11-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.00 Cr
as on 16-11-2024
- Revenue 3.09%
(FY 2023)
- Profit 12.37%
(FY 2023)
- Ebitda 9.14%
(FY 2023)
- Net Worth 86.27%
(FY 2023)
- Total Assets 116.09%
(FY 2023)
About Nd Pharma
The Company is engaged in the Mining Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹7.00 Cr.
Aditya Chopra and Satyendra Pawar serve as directors at the Company.
- CIN/LLPIN
U24232DL2010PTC207121
- Company No.
207121
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 2010
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nd Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aditya Chopra  | Director | 20-Jun-2023 | Current |
| Satyendra Pawar | Director | 24-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Nd Pharma.
Nd Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 3.09% increase. The company also saw a substantial improvement in profitability, with a 12.37% increase in profit. The company's net worth Soared by an impressive increase of 86.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nd Pharma?
In 2023, Nd Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Euphoria Khanij Private LimitedInactive For E-Filing 7 months 28 daysAditya Chopra is a mutual person
- New Eureka Mines And Minerals Private LimitedActive 3 years 1 month
Aditya Chopra is a mutual person
- Neuphoria Udyog Private LimitedInactive For E-Filing 9 months 17 days
Aditya Chopra is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 09 May 2022 | ₹7.00 Cr | Open |
How Many Employees Work at Nd Pharma?
Unlock and access historical data on people associated with Nd Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nd Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nd Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
